UY39328A - Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting - Google Patents
Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del stingInfo
- Publication number
- UY39328A UY39328A UY0001039328A UY39328A UY39328A UY 39328 A UY39328 A UY 39328A UY 0001039328 A UY0001039328 A UY 0001039328A UY 39328 A UY39328 A UY 39328A UY 39328 A UY39328 A UY 39328A
- Authority
- UY
- Uruguay
- Prior art keywords
- sting
- disease
- compositions
- activity
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación da a conocer entidades químicas (por ejemplo, un compuesto o una sal farmacéuticamente aceptable, y/o un hidrato, y/o un cocristal, y/o una combinación de fármacos del compuesto) que inhiben (por ejemplo, antagonizan) el estimulador de genes del interferón (STING). Dichas entidades químicas son útiles, por ejemplo, para tratar una afección, enfermedad o trastorno en el que el aumento (por ejemplo, excesivo) de la activación del STING (por ejemplo, la señalización del STING) contribuye a la enfermedad y/o los síntomas y/o la progresión de la enfermedad, afección o trastorno (por ejemplo, cáncer) en un sujeto (por ejemplo, un ser humano).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063052117P | 2020-07-15 | 2020-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39328A true UY39328A (es) | 2022-01-31 |
Family
ID=77249909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039328A UY39328A (es) | 2020-07-15 | 2021-07-15 | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4182028A1 (es) |
| JP (1) | JP2023540672A (es) |
| CN (1) | CN116528862A (es) |
| AR (1) | AR122976A1 (es) |
| TW (1) | TW202216685A (es) |
| UY (1) | UY39328A (es) |
| WO (1) | WO2022015957A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021529833A (ja) | 2018-07-03 | 2021-11-04 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| EP3846793B1 (en) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| WO2024059559A1 (en) * | 2022-09-12 | 2024-03-21 | Hotspot Therapeutics, Inc. | Isothiazolylcarboxamide compounds and their use in therapy |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| JPWO2005073210A1 (ja) * | 2004-01-28 | 2007-09-06 | キッセイ薬品工業株式会社 | 新規なベンゾフラン誘導体、それを含有する医薬組成物およびそれらの用途 |
| US8497285B2 (en) | 2010-12-03 | 2013-07-30 | The Trustees Of The University Of Pennsylvania | Therapy of autoimmune colitis using a TIP60 inhibitor |
| GB201201566D0 (en) * | 2012-01-30 | 2012-03-14 | Vernalis R&D Ltd | New chemical compounds |
| CN105744837B (zh) | 2013-10-21 | 2018-10-16 | 德雷克塞尔大学 | 治疗慢性乙型肝炎病毒感染的sting激动剂的用途 |
| EP3556362A1 (en) * | 2018-04-16 | 2019-10-23 | Ecole Polytechnique Federale De Lausanne (Epfl) | Sting inhibitors |
| TW202043198A (zh) * | 2019-01-17 | 2020-12-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關之病況的化合物及組合物 |
-
2021
- 2021-07-14 TW TW110125785A patent/TW202216685A/zh unknown
- 2021-07-15 JP JP2023502898A patent/JP2023540672A/ja active Pending
- 2021-07-15 CN CN202180063054.0A patent/CN116528862A/zh active Pending
- 2021-07-15 UY UY0001039328A patent/UY39328A/es unknown
- 2021-07-15 AR ARP210101985A patent/AR122976A1/es unknown
- 2021-07-15 EP EP21751933.9A patent/EP4182028A1/en active Pending
- 2021-07-15 WO PCT/US2021/041792 patent/WO2022015957A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| TW202216685A (zh) | 2022-05-01 |
| WO2022015957A1 (en) | 2022-01-20 |
| AR122976A1 (es) | 2022-10-19 |
| JP2023540672A (ja) | 2023-09-26 |
| EP4182028A1 (en) | 2023-05-24 |
| CN116528862A (zh) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39328A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting | |
| UY38751A (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting | |
| UY39005A (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting | |
| UY39006A (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting | |
| UY38905A (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting | |
| EA201891565A1 (ru) | Соединения и композиции для лечения состояний, ассоциированных с активностью sting | |
| UY39608A (es) | Compuestos y composiciones para tratar condiciones asociadas con la actividad de sting | |
| DOP2019000020A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| MX2018012249A (es) | Moduladores de nlpr3. | |
| ECSP21080535A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| MY194054A (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| CU20180143A7 (es) | 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas | |
| ECSP066457A (es) | 5-arilpirimidinas como agentes anti-cancer | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| AR112801A1 (es) | Inhibidores de cxcr-2 para tratar trastornos | |
| ECSP19014247A (es) | Formas de dosificación para tratar y prevenir trastornos del sueño | |
| ECSP23096498A (es) | Restos de administración terapéutica novedosos y usos de estos | |
| CL2020002465A1 (es) | Método de tratamiento de enfermedad fibrótica | |
| CL2023000856A1 (es) | Compuestos derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer | |
| EA201991147A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC | |
| ECSP22085221A (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| CL2021001623A1 (es) | Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer | |
| AR119033A1 (es) | Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa | |
| CL2021001389A1 (es) | Formulaciones en cápsula | |
| AR114306A1 (es) | Tratamiento y prevención de trastornos del sueño |